Company profile
REGENXBIO Inc.
NASDAQ: RGNX · Healthcare · Biotechnology
#301 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
54DFH 36DQ 72GM 62SS 68
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), workforce scale · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$87.8M
Rev growth YoY (TTM)
-44.0%
Net income (FY)
-$193.9M
Employees
371
as of 2026-08-11
Market cap
$538.7M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$170.4M$170.4M2025
Net income-$193.9M-$193.9M2025
Operating income-$161.2M-$161.2M2025
Total assets$453.0M$453.0M2025
Liabilities$350.3M$350.3M2025
Equity$102.7M$102.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Service92%
Service8%
By geography
Not disclosed.
The read
What is REGENXBIO Inc.’s revenue?
REGENXBIO Inc. booked $170.4M in FY2025 revenue, growing 105% year over year — faster than most Healthcare companies we track, at a -113.8% net margin.
Peers · Healthcare
Heartflow, Inc. Common Stock44DPhathom Pharmaceuticals, Inc.47DSyndax Pharmaceuticals, Inc.52DGinkgo Bioworks Holdings, Inc.44DMaze Therapeutics, Inc.49DPacific Biosciences of California, Inc.55CNeighbors
Montgomery →Key facts
CEOCurran Simpson
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeNASDAQ: RGNX
Employees371
IPO date2015-09-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.